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Abstract 
Objective.  Familial amyloid polyneuropathy (FAP) is an autosomal dominant form of 
hereditary amyloidosis.  Several studies reported coagulation factor X deficiency and 
excessive fibrinolysis in immunoglobulin light chain amyloidosis.  However, few have 
investigated coagulation and fibrinolysis in FAP.  The objective of this study was to 
determine abnormalities in plasma biomarkers of coagulation and fibrinolysis in FAP. 
Methods.  We prospectively recruited eight FAP patients with transthyretin mutations and 
ten age-matched control patients with other neuropathies in our university.  We examined 
plasma biomarkers of coagulation and fibrinolysis including prothrombin time, activated 
partial thromboplastin time, fibrinogen, fibrin/fibrinogen degradation products, D-dimer, 
α2-antiplasmin, antithrombin, plasminogen, thrombin-antithrombin complex, 
plasmin-α2-antiplasmin complex, prothrombin fragment 1+2, and coagulation factor X.  
The Mann-Whitney U test was performed for statistical comparisons between FAP and 
control groups. 
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Results.  FAP patients exhibited significantly decreased levels of coagulation factor X, 
plasminogen and α2-antiplasmin, and significantly increased levels of prothrombin 
fragment 1+2 compared to control patients. 
Conclusion.  Our results indicate abnormalities of coagulation and fibrinolysis in FAP 
patients. 
 
Keywords: amyloidosis, coagulation factor, prothrombin fragment, α2-antiplasmin, 
plasminogen 
 
Abbreviations: α2-AP = α2-antiplasmin; APTT = activated partial thromboplastin time; AL 
amyloidosis = immunoglobulin light chain amyloidosis; AT = antithrombin; CIDP = 
chronic inflammatory demyelinating neuropathy; F1+2 = plasma prothrombin fragment 1 + 
2; FAP = familial amyloid polyneuropathy; Fbg = fibrinogen; FDPs = fibrin/Fbg 
degradation products; FVIIa = activated coagulation factor VII; FX = coagulation factor X; 
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PAP = plasmin-α2-antiplasmin complex; PT = prothrombin time; TAT = 
thrombin-antithrombin complex; TTR = transthyretin 
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Introduction 
Familial amyloid polyneuropathy (FAP) is an autosomal dominant form of hereditary 
amyloidosis.  Amyloidogenic mutated transthyretin (TTR) is the most common 
FAP-related protein worldwide [1].  Several studies reported coagulation factor X (FX) 
deficiency and excessive fibrinolysis in immunoglobulin light chain amyloidosis (AL 
amyloidosis) patients [2-4].  However, few have investigated coagulation and fibrinolysis 
in FAP.  Most researchers did not observe coagulation abnormalities in FAP patients 
because of low incidence of hemorrhagic events [5].  Here we examined coagulation and 
fibrinolysis in FAP and observed decreased levels of FX, plasminogen, and α2-antiplasmin 
(α2-AP) and elevated levels of plasma prothrombin fragment 1 + 2 (F1+2). 
 
Patients and methods 
FAP patients  
We investigated coagulation and fibrinolysis in eight consecutive FAP patients 
admitted to our hospital from 2004 to 2011.  In our district, FAP with a TTR Val30Met 
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mutation was endemic [6], and a FAP pedigree with rare TTR Leu58Arg mutation was 
present [7].  Diagnoses were confirmed in all patients by positive family history, clinical 
and neurophysiological examinations, tissue biopsies of the sural nerve and gastrointestinal 
tract demonstrating amyloid deposits, and gene analysis indicating the TTR Val30Met (n = 
7) or Leu58Arg mutations (n = 1).  All patients were from separate kinships.  Patient age 
ranged from 34 to 77 years (median age: 66 years); six of the eight patients were males and 
two were females.  Three patients experienced hemorrhagic events: one had intestinal 
hemorrhage, one had hematuria and a hemorrhagic kidney cyst on abdominal computed 
tomography, and one had seminal vesicle hemorrhage; no patient experienced serious 
hemorrhagic events requiring blood transfusion or resulting in death.  All patients had no 
genetic abnormalities of coagulation and fibrinolysis. All patients had no liver dysfunction 
and showed normal levels of transaminase, albumin, and choline esterase (data not shown). 
Control patients   
We prospectively recruited control patients with peripheral neuropathy at our hospital.  
Each peripheral neuropathy was diagnosed by clinical, laboratory, and neurophysiological 
Ryoichi Takahashi - 8 - 
 
examinations, and nerve biopsy.  We excluded patients being administered anticoagulation 
drugs and those having severe hepatic injury or innate coagulopathy.  The age of ten 
control patients with peripheral neuropathies ranged from 57 to 67 years (median age: 61 
years; not significantly different from that of FAP patients).  Diagnoses included alcoholic 
neuropathy (n = 3), diabetic neuropathy (n = 2), vasculitic neuropathy (n = 1), Crow-Fukase 
syndrome (n = 1), neuropathy with anti-myelin-associated glycoprotein antibody (n = 1), 
chronic inflammatory demyelinating neuropathy (CIDP) (n = 1), and Charcot-Marie-Tooth 
disease (n = 1). 
Coagulation and fibrinolysis tests  
This study was approved by the medical ethical committee of our university.  After 
obtaining written informed consent, blood samples were obtained from all FAP and control 
patients.  Plasma samples were analyzed for prothrombin time (PT), activated partial 
thromboplastin time (APTT), fibrinogen (Fbg), fibrin/Fbg degradation products (FDPs), 
D-dimer, α2-AP, antithrombin (AT), plasminogen, thrombin-antithrombin complex (TAT), 
plasmin-α2-antiplasmin complex (PAP), F1+2, and FX.  PT and APTT were measured by 
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light scattering spectroscopy using diagnostic kits (PT: Thromborel S, Siemens Healthcare 
Diagnostics, Inc.  APTT: Actin FSL, Siemens Healthcare Diagnostics, Inc.).  Fbg and FX 
were measured by the coagulation time method using reagents (Fbg: Fibrinogen 
determination; Siemens Healthcare Diagnostics, Inc.  FX: HemosIL Factor X deficient 
plasma and HemosIL Recombiplastin; Mitsubishi Chemical Medience Co., Ltd., Japan).  
FDP was measured by latex photometric immunoassay using a diagnostic kit (Nanopia 
P-FDP; Sekisui Medical Co., Ltd., Japan).  AT, α2-AP, and plasminogen were measured 
using synthetic chromogenic peptide substrate (AT: Test Team S AT III, Sekisui Medical 
Co., Ltd., Japan.  α2-AP: Test Team S APL; Sekisui Medical Co., Ltd., Japan.  
Plasminogen: test team S PLG; Sekisui Medical Co., Ltd., Japan).  TAT, PAP, and F1+2 
were measured by enzyme immunoassay , latex agglutination turbidimetric immunoassay, 
and enzyme-linked immunosorbent assay using diagnostic kits (TAT: TAT S; TFB Co., Ltd., 
Japan.  PAP: LPIA-S PPI II; Mitsubishi Chemical Medience Co., Ltd., Japan.  F1+2: 
EnzygnostF1+2 Monoclonal; Siemens Healthcare Diagnostics, Inc., Japan), respectively. 
The two patient groups were statistically compared using the Mann-Whitney U test.  
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Statistical analyses were performed using software package StatView version 5.0.  P 
values <0.05 were considered significant. 
 
Results   
The table 1 shows the coagulation and fibrinolysis test results of FAP and control 
patients.  The levels of α2-AP, plasminogen, F1+2, and FX were abnormal in the FAP 
group but not in the control group.  FAP patients exhibited significantly decreased levels 
of α2-AP (p = 0.039), plasminogen (p = 0.0037), and FX (p = 0.0010), and significantly 
elevated levels of F1+2 (p = 0.019) compared with control patients. 
Some FAP patients also presented with prolonged PT (n = 2), elevated TAT level (n = 
1), and mildly elevated PAP levels (n = 4).  No abnormalities were observed in levels of 
Fbg, FDP, or D-dimer in FAP patients. 
Some control patients exhibited prolonged PT (n = 1), elevated TAT levels (n = 2), and 
elevated levels of F1+2 (n = 4).  However, no abnormalities were observed in levels of 
α2-AP, Plg, Fbg, FDP, D-dimer, or FX. 




Our results indicate coagulation and fibrinolysis abnormalities in FAP patients.  
The figure 1 shows the coagulation and fibrinolysis cascades and the abnormalities 
observed in FAP patients.  For coagulation markers, we observed significant elevation of 
F1+2 and decrease of FX in FAP patients.  F1+2 is an activation peptide generated during 
prothrombin conversion to thrombin, and the elevation of F1+2 indicates in vivo thrombin 
generation, which means the activation of coagulation.  Among fibrinolysis markers, we 
observed significantly decreased levels of α2-AP and plasminogen.  PAP was elevated in 
FAP patients compared to normal value, but this elevation of PAP was not significant.  The 
decreased levels of α2-AP and plasminogen indicate the activation of fibrinolysis.  Our 
FAP patients had no liver dysfunction, congenital blood coagulation disorders, or 
thrombotic disorders, such as atherosclerosis, thromboembolism, inflammation, cancer, 
sepsis, and atrial fibrillation [8]. 
As for the mechanisms underlying the activation of coagulation and fibrinolysis in 
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FAP, we speculate that the injury of vascular endothelial cells by amyloid deposits might 
lead to expression of tissue factor and initiate the extrinsic pathway of the clotting cascades, 
activating coagulation.  The activation of coagulation by amyloid deposits might trigger 
secondary fibrinolysis.  However, as discussed below, further investigations are necessary 
to understand the mechanism by which activation of coagulation and fibrinolysis occurs in 
FAP patients. 
F1+2 and TAT are biomarkers of thrombosis, and, commonly, F1+2 plasma 
concentration is correlated with that of TAT in thrombosis [9].  In our study, TAT levels 
were not elevated despite thrombin neutralization by antithrombin-mediated TAT 
generation.  The reason why TAT was not elevated in FAP patients might be explained by 
the shorter half-life of TAT (5 min versus 90 min for F1+2) [10-11].  The decrease of 
α2-AP and plasminogen could indicate the activation of fibrinolysis; however, PAP was not 
significantly elevated.  It was reported that the levels of PAP were significantly elevated in 
the patients of AL and AA amyloidoses, which would be related to pathological bleeding, 
but the PAP levels were not elevated in FAP [2], compatible with our results; this would be 
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consistent with less severe bleeding tendency in FAP compared with AL and AA 
amyloidoses [3].  In our study, we found the mild activation of coagulation and 
fibrinolysis in FAP patients.  The half-life (0.5 days) of PAP is shorter compared with that 
of plasminogen (2.2 days) and α2-AP (2.6 days) [12-13] during the activation of fibrinolysis.  
The shorter half-life of PAP as well as mild activation of fibrinolysis might be related to 
insignificant elevation of PAP in FAP.  Further, it remains to be determined why the FDP 
levels were not elevated in spite of activation of fibrinolysis in FAP patients, though we 
speculate that the FDP levels were unchanged because the activation of fibrinolysis was 
very mild. 
Decreased FX was also observed in FAP patients.  Decrease of FX may be 
explained by FX consumption due to excessive coagulation.  On the other hand, 
deficiencies of coagulation factors such as FX have been reported in AL amyloidosis [3].  
FX deficiency has been demonstrated to be due to in vivo binding of FX to the amyloid 
fibrils [14].  FX binding to amyloid fibrils may occur in FAP as well as AL amyloidosis.  
However, there is no immunohistochemical proof of FX binding to FAP amyloid deposits.   
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Thus, we first demonstrated that the coagulation and fibrinolysis cascades were 
activated in FAP.  Our study has certain limitations.  The sample size was relatively small.  
Patients with AL or other amyloidoses were not examined.  A prospective study with a 
large sample size should be conducted to confirm coagulation and fibrinolysis 
abnormalities in FAP. 
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Table 1. Tests for coagulation and fibrinolysis in FAP and control patients. 
Values are median values ± quartile deviation.  * p < 0.05, ** p < 0.01. 
 Normal range  FAP Other neuropathies  p-value 
Male/Female   6/2 6/4   
Age   66.5 ± 5.0 (n = 8) 61.5 ± 2.88 (n = 10)  0.267 
PT (s) 10.5-13.5  12.3 ± 0.59 (n = 8) 11.7 ± 0.43 (n = 10)  0.11 
APTT (s) 24.3-36.0  28.3 ± 1.81 (n = 8) 25.8 ± 2.26 (n = 10)  0.13 
Fbg (mg/dL) 150-400  265.5 ± 23.3 (n = 8) 309.0 ± 38.9 (n = 10)  0.17 
FDPs (μg/mL) <4  1.6 ± 0.58 (n = 8) 1.1 ±0.78 (n = 10)  0.35 
α2-AP (%) 85-115 ↓ 80.0 ± 5.13 (n = 6) 108.5 ± 14.3 (n = 8)  0.039* 
AT (%) 70-130  92.0 ± 6.75 (n = 7) 105.0 ±2.0 (n = 5)  0.09 
Plg (%) 75-125 ↓ 76.0 ± 6.75 (n = 6) 99.0 ± 8.63 (n = 9)  0.0037** 
TAT (ng/mL) <3.0  1.3 ± 0.3 (n = 8) 1.8 ± 0.61 (n = 10)  0.16 
PAP (μg/mL) <0.8  1.0 ± 0.16 (n = 8) 0.8 ±0.23 (n = 10)  0.29 
F1+2 (pmol/L) 69-229 ↑ 281.0 ± 51.4 (n = 8) 197.0 ±36.0 (n = 10)  0.019* 
FX (%) 70-130 ↓ 62.0 ± 3.5 (n = 8) 92.5 ± 9.0 (n = 10)  0.0010** 
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Figure legend: 
Figure 1. Coagulation and fibrinolysis cascades. 
FAP patients showed elevated F1+2 and decreased FX, plasminogen and α2-AP levels, 
indicating activation of coagulation and fibrinolysis. 
 

